公开(公告)号：US20230257708A1

公开(公告)日：2023-08-17

申请号：US18164989

申请日：2023-02-06

申请人： National Cancer Center Japan ,  Kyoto University ,  Takeda Pharmaceutical Company Limited

发明人： Tetsuya Nakatsura ,  Toshiaki Yoshikawa ,  Yasushi Uemura ,  Kyoko Fukuda ,  Shin Kaneko ,  Atsutaka Minagawa ,  Yoshiaki Kassai ,  Atsushi Matsuda

IPC分类号： C12N5/0783 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C12N15/86

CPC分类号： C12N5/0638 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C12N15/86 ,  C12N2506/45

摘要： Provided is a T cell receptor containing, as α chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as β chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor containing, as an α chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 13 to 15, as β chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 16 to 18, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02.

公开(公告)号：US11603519B2

公开(公告)日：2023-03-14

申请号：US16483876

申请日：2018-02-05

申请人： National Cancer Center Japan ,  Kyoto University ,  Takeda Pharmaceutical Company Limited

发明人： Tetsuya Nakatsura ,  Toshiaki Yoshikawa ,  Yasushi Uemura ,  Kyoko Fukuda ,  Shin Kaneko ,  Atsutaka Minagawa ,  Yoshiaki Kassai ,  Atsushi Matsuda

IPC分类号： C12N5/0783 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C12N15/86

摘要： Provided is a T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02. Disclosed T cell receptors are useful in treating or avoiding cancers which are associated with expression of glypican-3.

公开(公告)号：US20200010804A1

公开(公告)日：2020-01-09

申请号：US16483876

申请日：2018-02-05

申请人： National Cancer Center Japan ,  Kyoto University ,  Takeda Pharmaceutical Company Limited

发明人： Tetsuya Nakatsura ,  Toshiaki Yoshikawa ,  Yasushi Uemura ,  Kyoko Fukuda ,  Shin Kaneko ,  Atsutaka Minagawa ,  Yoshiaki Kassai ,  Atsushi Matsuda

IPC分类号： C12N5/0783 ,  C07K14/725 ,  C12N15/86 ,  A61P35/00 ,  A61K35/17

摘要： Provided is a T cell receptor containing, as α chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as β chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor containing, as an α chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 13 to 15, as β chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 16 to 18, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02.